NCT06431243View on ClinicalTrials.gov

A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

May 8, 2024

Primary Completion Date

May 1, 2026

Study Completion Date

November 1, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

A0/B0 group Purinostat Mesylate 11.2mg/m2

Purinostat Mesylate 11.2mg/m2

DRUG

A0/B0 group Purinostat Mesylate 15mg/m2

Purinostat Mesylate 15mg/m2

DRUG

A group Purinostat Mesylate 6mg/m2

Purinostat Mesylate 6mg/m2 + FS 500mg

DRUG

A group Purinostat Mesylate 8.4mg/m2

Purinostat Mesylate 8.4mg/m2 + FS 500mg

DRUG

A group Purinostat Mesylate 11.2mg/m2

Purinostat Mesylate 11.2mg/m2 + FS 500mg

DRUG

A group Purinostat Mesylate 15 mg/m2

Purinostat Mesylate 15 mg/m2 + FS 500mg

DRUG

B group Purinostat Mesylate 6 mg/m2

Purinostat Mesylate 6mg/m2 + Tislelizumab 200mg

DRUG

B group Purinostat Mesylate 8.4 mg/m2

Purinostat Mesylate 8.4mg/m2 + Tislelizumab 200mg

DRUG

B group Purinostat Mesylate 11.2mg/m2

Purinostat Mesylate 11.2mg/m2 + Tislelizumab 200mg

DRUG

B group Purinostat Mesylate 15mg/m2

Purinostat Mesylate 15mg/m2 + Tislelizumab 200mg

Trial Locations (2)

510000

RECRUITING

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guanzhou

610000

RECRUITING

West China hospital of Sichuan university, Chengdu

All Listed Sponsors
lead

Chengdu Zenitar Biomedical Technology Co., Ltd

INDUSTRY